Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Top Cited Papers
- 22 April 2015
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 520 (7549) , 692-696
- https://doi.org/10.1038/nature14426
Abstract
The authors show that a large fraction of tumour mutations is immunogenic and predominantly recognized by CD4+ T cells; they use these data to design synthetic messenger-RNA-based vaccines specific against tumour mutations, and show that these can reject tumours in mice. Sebastian Kreiter et al. demonstrate in three independent murine tumour models that many non-synonymous cancer mutations are immunogenic and, surprisingly, most of these are recognized by CD4+ T cells. Mutation based synthetic mRNA based vaccines are shown to result in rejection of tumors in mice. The authors demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers, suggesting that the tailored immunotherapy approach introduced here may serve as a model for the effective targeting of individual patient's tumours with vaccines produced 'just in time'. Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient’s tumour possesses a unique set of mutations (‘the mutanome’) that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient’s individual tumour-specific mutations1. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4+ T cells. Vaccination with such CD4+ immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4+ T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient’s tumour with vaccines produced ‘just in time’.Keywords
This publication has 30 references indexed in Scilit:
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivoGene Therapy, 2010
- Adaptive immunity maintains occult cancer in an equilibrium stateNature, 2007
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cellsBlood, 2006
- Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor AntigenScience, 1999
- Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.The Journal of Immunology, 1997
- A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human MelanomaScience, 1995